Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B

Xianhua Mao, Lung Yi Mak, Wai-Kay Seto

Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0173

View: 1784 Download: 80 Web of Science: 1 Crossref: 1

Review

Acute-on-chronic liver failure: Terminology, mechanisms and management

Vinay Kumar BR, Shiv Kumar Sarin

Clin Mol Hepatol. 2023;29(3):670-689. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0103

View: 4837 Download: 610 Web of Science: 6 Crossref: 6

A decade of liver organoids: Advances in disease modeling

Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, Junjun Ding, Yun-Shen Chan

Clin Mol Hepatol. 2023;29(3):643-669. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0428

View: 8342 Download: 263 Crossref: 1

Acute hepatitis C virus infection: clinical update and remaining challenges

Chen-Hua Liu, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):623-642. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0349

View: 4336 Download: 360 Web of Science: 7 Crossref: 9

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection

Chih-Lin Lin, Jia-Horng Kao

Clin Mol Hepatol. 2023;29(3):605-622. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2022.0342

View: 3932 Download: 285 Web of Science: 6 Crossref: 11

Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity

Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2023;29(3):593-604. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2022.0391

View: 3543 Download: 307 Web of Science: 4 Crossref: 5

Guideline

KASL clinical practice guidelines for management of autoimmune hepatitis 2022

Clin Mol Hepatol. 2023;29(3):542-592. Published online May 3, 2023

DOI: https://doi.org/10.3350/cmh.2023.0087

View: 3199 Download: 275 Web of Science: 1 Crossref: 3

Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association

Yuri Cho, Jin Woo Choi, Hoon Kwon, Kun Yung Kim, Byung Chan Lee, Hee Ho Chu, Dong Hyeon Lee, Han Ah Lee, Gyoung Min Kim, Jung Suk Oh, Dongho Hyun, In Joon Lee, Hyunchul Rhim

Clin Mol Hepatol. 2023;29(3):521-541. Published online July 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0202

View: 2709 Download: 178 Web of Science: 3 Crossref: 3

Snapshot

Systemic therapy in advanced hepatocellular carcinoma

Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):516-519. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0051

View: 3260 Download: 158 Web of Science: 3 Crossref: 3

Correspondence

Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”

Jeong-Ju Yoo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):513-515. Published online February 15, 2023

DOI: https://doi.org/10.3350/cmh.2023.0044

View: 2049 Download: 42

Letter to the Editor

Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”

Chia-Ming Chu, Yun-Fan Liaw

Clin Mol Hepatol. 2023;29(2):510-512. Published online January 30, 2023

DOI: https://doi.org/10.3350/cmh.2023.0018

View: 2135 Download: 63 Web of Science: 1 Crossref: 1

Original Article

Next-generation sequencing analysis of hepatitis C virus resistance–associated substitutions in direct-acting antiviral failure in South Korea

Kyung-Ah Kim, Sejoon Lee, Hye Jung Park, Eun Sun Jang, Youn Jae Lee, Sung Bum Cho, Young Suk Kim, In Hee Kim, Byung Seok Lee, Woo Jin Chung, Sang Hoon Ahn, Seungtaek Kim, Sook Hyang Jeong

Clin Mol Hepatol. 2023;29(2):496-509. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2022.0345 Correction in: Clin Mol Hepatol 2023;29(3):830

View: 3211 Download: 132 Web of Science: 1 Crossref: 1

Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase

Jeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kim

Clin Mol Hepatol. 2023;29(2):482-495. Published online January 5, 2023

DOI: https://doi.org/10.3350/cmh.2022.0322

View: 3397 Download: 182 Web of Science: 9 Crossref: 10

Taurocholic acid promotes hepatic stellate cell activation via S1PR2/p38 MAPK/YAP signaling under cholestatic conditions

Jing Yang, Xujiao Tang, Zhu Liang, Mingzhu Chen, Lixin Sun

Clin Mol Hepatol. 2023;29(2):465-481. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2022.0327

View: 4586 Download: 222 Web of Science: 3 Crossref: 6

Factors associated with unrecognized cirrhosis in patients with hepatocellular carcinoma

Yi-Te Lee, Mohammad A. Karim, Hye Chung Kum, Sulki Park, Nicole E. Rich, Mazen Noureddin, Amit G. Singal, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):453-464. Published online February 1, 2023

DOI: https://doi.org/10.3350/cmh.2022.0450

View: 3275 Download: 114 Web of Science: 2 Crossref: 2

Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study

Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith

Clin Mol Hepatol. 2023;29(2):433-452. Published online January 4, 2023

DOI: https://doi.org/10.3350/cmh.2022.0316

View: 5174 Download: 226 Web of Science: 11 Crossref: 13

Single-cell phenotypes of peripheral blood immune cells in early and late stages of non-alcoholic fatty liver disease

Kathryn Jane Waller, Hajar Saihi, Wenhao Li, James Hallimond Brindley, Anja De Jong, Wing-kin Syn, Conrad Bessant, William Alazawi

Clin Mol Hepatol. 2023;29(2):417-432. Published online November 21, 2022

DOI: https://doi.org/10.3350/cmh.2022.0205

View: 4710 Download: 164 Web of Science: 2 Crossref: 4

Editorial

The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review

Young-Joo Jin

Clin Mol Hepatol. 2023;29(2):414-416. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0055

View: 4025 Download: 62

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease

Byeong Geun Song, Dong Hyun Sinn

Clin Mol Hepatol. 2023;29(2):411-413. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0058

View: 2008 Download: 46 Web of Science: 1 Crossref: 1

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease

Ji-Won Park, Ki Tae Suk

Clin Mol Hepatol. 2023;29(2):408-410. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0085

View: 2234 Download: 67 Web of Science: 2 Crossref: 2

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?

Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang

Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0069

View: 2512 Download: 69 Web of Science: 2 Crossref: 2

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future

Kee-Huat Chuah, Wah-Kheong Chan

Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0062

View: 2339 Download: 57 Web of Science: 1 Crossref: 2

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease

Maamon Basheer, Mohamed Naffaa, Nimer Assy

Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0045

View: 2706 Download: 122

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

Lynna Alnimer, Mazen Noureddin

Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023

DOI: https://doi.org/10.3350/cmh.2023.0104

View: 2427 Download: 81 Web of Science: 1

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed

Philipp Kasper, Münevver Demir, Hans-Michael Steffen

Clin Mol Hepatol. 2023;29(2):390-393. Published online March 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0059

View: 2358 Download: 53 Web of Science: 2 Crossref: 2

Implications of comorbidities in nonalcoholic fatty liver disease

Sherlot Juan Song, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0066

View: 2784 Download: 73 Web of Science: 1 Crossref: 1

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 2526 Download: 75 Web of Science: 2 Crossref: 2

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 2278 Download: 93 Web of Science: 2 Crossref: 1

The growing burden of non-alcoholic fatty liver disease on mortality

Ju-Yeon Cho, Won Sohn

Clin Mol Hepatol. 2023;29(2):374-376. Published online March 6, 2023

DOI: https://doi.org/10.3350/cmh.2023.0084

View: 2169 Download: 63

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology

Eileen Laurel Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0086

View: 2544 Download: 111 Web of Science: 3 Crossref: 3

Viewed By 5378	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5336	MAFLD: How is it different from NAFLD?
Viewed By 5226	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3904	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3871	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

Article category